These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1229 related items for PubMed ID: 16083542

  • 21. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P, Tsolaki M, Hort J, Hager K, Soininen H, López Pousa S, Li C, Schwam E.
    Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
    [Abstract] [Full Text] [Related]

  • 22. Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
    Caffarra P, Vezzadini G, Copelli S, Dieci F, Messa G, Nonis E, Venneri A.
    Acta Biomed; 2007 Dec; 78(1):16-21. PubMed ID: 17687812
    [Abstract] [Full Text] [Related]

  • 23. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R, EXPRESS Investigators.
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A, Spiegel R, Quarg P.
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [Abstract] [Full Text] [Related]

  • 25. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernández-Ferràndiz M, Morante-Muñoz V, Isern-Vila A, Gelada-Batlle E, Majó-Llopart J.
    Dement Geriatr Cogn Disord; 2005 Mar; 19(4):189-95. PubMed ID: 15677866
    [Abstract] [Full Text] [Related]

  • 26. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
    Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I.
    Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
    [Abstract] [Full Text] [Related]

  • 27. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V, Haglund A, Kowalski J, Langworth S, Winblad B.
    Dement Geriatr Cogn Disord; 2008 Jan; 26(5):458-66. PubMed ID: 18984956
    [Abstract] [Full Text] [Related]

  • 28. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R.
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [Abstract] [Full Text] [Related]

  • 29. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F.
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [Abstract] [Full Text] [Related]

  • 30. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D.
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [Abstract] [Full Text] [Related]

  • 31. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
    Bullock R, Dengiz A.
    Int J Clin Pract; 2005 Jul; 59(7):817-22. PubMed ID: 15963209
    [Abstract] [Full Text] [Related]

  • 32. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A, Ziolkowska-Kochan M, Rybakowski JK.
    Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
    [Abstract] [Full Text] [Related]

  • 33. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [Abstract] [Full Text] [Related]

  • 34. Rivastigmine for Alzheimer's disease.
    Desai AK, Grossberg GT.
    Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
    [Abstract] [Full Text] [Related]

  • 35. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR.
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [Abstract] [Full Text] [Related]

  • 36. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C, Jiménez Caballero PE, Alfonso V, González-Adalid M.
    Dement Geriatr Cogn Disord; 2009 Jun; 28(3):196-205. PubMed ID: 19738386
    [Abstract] [Full Text] [Related]

  • 37. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
    Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R.
    Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
    [Abstract] [Full Text] [Related]

  • 38. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
    Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Haglund A, Zhang R, Schindler R.
    Dement Geriatr Cogn Disord; 2006 Nov; 21(5-6):353-63. PubMed ID: 16508298
    [Abstract] [Full Text] [Related]

  • 39. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, Lane R.
    Neurology; 2007 Jul 24; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [Abstract] [Full Text] [Related]

  • 40. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group.
    Alzheimer Dis Assoc Disord; 2006 Jul 24; 20(4):263-8. PubMed ID: 17132971
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 62.